Royal Alexandra Hospital Critical Care Research and Quality Assurance Group
Royal Alexandra Hospital Critical Care Research and Quality Assurance Group
Site Lead Investigator: Dr. J Kutsogiannis
About the site:
The RAH Critical Care Research and Quality Assurance Group was established in the mid 80’s by Dr.’s T. Noseworthy, R. Johnston and A. Shustack. Today the group is led by Dr. J. Kutsogiannis.
Dr. Kutsogiannis has been the Director of Research for just short of 20 years. He is a full professor in the Department of Critical Care at the University of Alberta with a Masters of Health Science- Clinical Epidemiology, Adjunct Professor, School of Public Health, University of Alberta, and President, Canadian Neuro-Critical Care Society.
Dr. Kutsogiannis is fully engaged with, and has supported the Canadian Critical Care Trials Group programs for over 25 years. The group has assisted in the advancement of individual researchers within AHS by providing ongoing support and/or mentorship with their projects and publications, provided knowledge translation of our research initiatives and those of other researchers (including quality assurance projects into improving the quality of care provided to patients), continues to expand our investigator initiated protocol development and increase our publication portfolio, supports career development of newer intensivists, cooperates with the Critical Care SCN to roll out provincial initiatives, and is currently working collaboratively with the neurosurgical department.
The RAH Critical Care Research office consists of: Research Director (Jim Kutsogiannis, MD, MHS, FRCPC), Research Manager (Patrica Thompson RN, CCRP) and Administrative Assistant/Research Coordinator (Tayne Hewer, M.Sc).
| Theme | Current Project | Invesitgator |
| Infectious Disease | A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Septic Intensive Care Unit Patients (LOVIT) | Dr. J Kutsogiannis |
| Neurosciences | HEMOglobin transfusion threshold in Traumatic brain Injury OptimizatioN: The HEMOTION TRIAL PROTOCOL | Dr. J Kutsogiannis |
| Neurosciences | Aneurysmal Subarachnoid Hemorrhage - Red Blood Cell Transfusion and Outcome (SAHaRA) | Dr. J Kutsogiannis |
| Respiratory Science | The measurement of Cough Peak Flows to predict liberation from mechanical ventilation or tracheostomy in respiratory and neurological subgroups of critically ill patients (CPF) | Dr. J Kutsogiannis |
| Respiratory Science | The Use of Capnographic Late Dead Space Fraction and Clinical Prediction Rules in the Prediction of Pulmonary Embolism in Critically Ill Patients Undergoing Computed Tomography of the Chest or Ventilation Perfusion Scanning (Deadspace) | Dr. J Kutsogiannis |
| Respiratory Science | The Frequency of Screening and SBT Technique Trial: The FAST Trial A North American Weaning Collaboration (FAST) | Dr. J Kutsogiannis |
| Neurosciences | The New Edmonton Cervical Spine Board: (NECs Board) Trial |
Dr. Fox |
| Neurosciences | Nimodipine Pharmacokinetic Variability and its Impact on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage: A Prospective Observational Study (Nimodipine) |
Dr. Mahmoud |
|
|
PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a double-blind Randomized Controlled Trial (PROTEST) | Dr. J Kutsogiannis |
| Neurosciences | Sedation, Analgesia and Delirium MANagement: an international audit of adult medical, surgical, trauma, and neuro-intensive care patients | Dr. J Kutsogiannis |
| Infectious Disease | Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | Dr. J Kutsogiannis |
| Covid-19 Studies | ||
| Infectious Disease | Neurological Complications of COVID 19 | Dr. J Kutsogiannis |
| Infectious Disease | Canadian Severe Acute Infection Outbreak and Pandemic Preparedness Study: Short Period Incidence Study of Severe Acute Respiratory Infection (Sprint-Sari) |
Dr. O Rewa |
| Infectious Disease | A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO) |
Dr. G Singh |
| Infectious Disease | Lessening Organ Dysfunction with VITamin C; A Multicentre Concealed-Allocation Parallel-Group Blinded Randomized Controlled Trial to Ascertain the Effect of High-Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Hospitalized Patients with COVID-19 (Lovit-Covid) | Dr. J Kutsogiannis |